Cincinnati Children's Hospital Medical Center, along with two other
institutions, has licensed technology to a Massachusetts-based startup
company called Glycosyn Inc. 

Glycosyn, founded by researcher David Newburg, will develop products in the
areas of infectious disease, allergy and obesity from the licensed
technology. 

All of the patents licensed by Glycosyn relate to the role of human milk in
infant nutrition and health, and were developed at Cincinnati Children's and
its collaborating universities through a grant funded by the National
Institute of Child Health and Development. 

The other two institutions -- the University of Massachusetts Medical
School, and the Instituto Nacional de Ciencias Medicas y Nutricion in Mexico
City, are joint owners of the Glycosyn technology.

[snip]

The investigators are studying the innate components of human milk to
determine which ones confer protection from infection. Glycosyn hopes to be
able to synthesize the active components in human milk for future clinical
applications.

Children's licenses technology to biomed firm
http://cincinnati.bizjournals.com/cincinnati/stories/2004/10/11/daily46.html
?jst=b_ln_hl
Your shorter link is: http://makeashorterlink.com/?Y23B52A89


Related Story:  Children's Goes to Market
http://www.bizjournals.com/cincinnati/stories/2004/08/02/story4.html?jst=s_c
n_hl
Your shorter link is: http://makeashorterlink.com/?F34B41A89



Arly Helm, MS, IBCLC

             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(R)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html